Eintrag weiter verarbeiten
Topiramate for Weight Reduction in Adolescents With Severe Obesity
Gespeichert in:
| Zeitschriftentitel: | Clinical Pediatrics |
|---|---|
| Personen und Körperschaften: | , , , |
| In: | Clinical Pediatrics, 54, 2015, 1, S. 19-24 |
| Format: | E-Article |
| Sprache: | Englisch |
| veröffentlicht: |
SAGE Publications
|
| Schlagwörter: |
| author_facet |
Fox, Claudia K. Marlatt, Kara L. Rudser, Kyle D. Kelly, Aaron S. Fox, Claudia K. Marlatt, Kara L. Rudser, Kyle D. Kelly, Aaron S. |
|---|---|
| author |
Fox, Claudia K. Marlatt, Kara L. Rudser, Kyle D. Kelly, Aaron S. |
| spellingShingle |
Fox, Claudia K. Marlatt, Kara L. Rudser, Kyle D. Kelly, Aaron S. Clinical Pediatrics Topiramate for Weight Reduction in Adolescents With Severe Obesity Pediatrics, Perinatology and Child Health |
| author_sort |
fox, claudia k. |
| spelling |
Fox, Claudia K. Marlatt, Kara L. Rudser, Kyle D. Kelly, Aaron S. 0009-9228 1938-2707 SAGE Publications Pediatrics, Perinatology and Child Health http://dx.doi.org/10.1177/0009922814542481 <jats:p> Background. Medications for use as an adjunct to lifestyle modification therapy (LSM) for severe adolescent obesity are limited. Topiramate results in weight reduction in adults with obesity, but has not been studied in adolescents. Objective. To examine the effect of topiramate plus LSM on body mass index (BMI) reduction in adolescents with severe obesity. Methods. Data for this retrospective chart review were collected from patients attending a pediatric weight management program who were treated with LSM plus topiramate for 3 months minimum. Mean BMI percent change from baseline was evaluated using t-tests. Results. Twenty-eight patients (mean age 15.2 ± 2.5 years, mean baseline BMI 46.2 ± 10.3 kg/m<jats:sup>2</jats:sup>) were identified for inclusion. The 6-month percent change in BMI was −4.9, 95% confidence interval (−7.1, −2.8), P < .001. Conclusions. Topiramate with concurrent LSM was associated with clinically meaningful BMI reduction in adolescents with severe obesity. Randomized controlled clinical trials examining efficacy and safety of topiramate for severe obesity in adolescents are needed. </jats:p> Topiramate for Weight Reduction in Adolescents With Severe Obesity Clinical Pediatrics |
| doi_str_mv |
10.1177/0009922814542481 |
| facet_avail |
Online |
| format |
ElectronicArticle |
| fullrecord |
blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE3Ny8wMDA5OTIyODE0NTQyNDgx |
| id |
ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE3Ny8wMDA5OTIyODE0NTQyNDgx |
| institution |
DE-105 DE-14 DE-Ch1 DE-L229 DE-D275 DE-Bn3 DE-Brt1 DE-D161 DE-Gla1 DE-Zi4 DE-15 DE-Pl11 DE-Rs1 |
| imprint |
SAGE Publications, 2015 |
| imprint_str_mv |
SAGE Publications, 2015 |
| issn |
0009-9228 1938-2707 |
| issn_str_mv |
0009-9228 1938-2707 |
| language |
English |
| mega_collection |
SAGE Publications (CrossRef) |
| match_str |
fox2015topiramateforweightreductioninadolescentswithsevereobesity |
| publishDateSort |
2015 |
| publisher |
SAGE Publications |
| recordtype |
ai |
| record_format |
ai |
| series |
Clinical Pediatrics |
| source_id |
49 |
| title |
Topiramate for Weight Reduction in Adolescents With Severe Obesity |
| title_unstemmed |
Topiramate for Weight Reduction in Adolescents With Severe Obesity |
| title_full |
Topiramate for Weight Reduction in Adolescents With Severe Obesity |
| title_fullStr |
Topiramate for Weight Reduction in Adolescents With Severe Obesity |
| title_full_unstemmed |
Topiramate for Weight Reduction in Adolescents With Severe Obesity |
| title_short |
Topiramate for Weight Reduction in Adolescents With Severe Obesity |
| title_sort |
topiramate for weight reduction in adolescents with severe obesity |
| topic |
Pediatrics, Perinatology and Child Health |
| url |
http://dx.doi.org/10.1177/0009922814542481 |
| publishDate |
2015 |
| physical |
19-24 |
| description |
<jats:p> Background. Medications for use as an adjunct to lifestyle modification therapy (LSM) for severe adolescent obesity are limited. Topiramate results in weight reduction in adults with obesity, but has not been studied in adolescents. Objective. To examine the effect of topiramate plus LSM on body mass index (BMI) reduction in adolescents with severe obesity. Methods. Data for this retrospective chart review were collected from patients attending a pediatric weight management program who were treated with LSM plus topiramate for 3 months minimum. Mean BMI percent change from baseline was evaluated using t-tests. Results. Twenty-eight patients (mean age 15.2 ± 2.5 years, mean baseline BMI 46.2 ± 10.3 kg/m<jats:sup>2</jats:sup>) were identified for inclusion. The 6-month percent change in BMI was −4.9, 95% confidence interval (−7.1, −2.8), P < .001. Conclusions. Topiramate with concurrent LSM was associated with clinically meaningful BMI reduction in adolescents with severe obesity. Randomized controlled clinical trials examining efficacy and safety of topiramate for severe obesity in adolescents are needed. </jats:p> |
| container_issue |
1 |
| container_start_page |
19 |
| container_title |
Clinical Pediatrics |
| container_volume |
54 |
| format_de105 |
Article, E-Article |
| format_de14 |
Article, E-Article |
| format_de15 |
Article, E-Article |
| format_de520 |
Article, E-Article |
| format_de540 |
Article, E-Article |
| format_dech1 |
Article, E-Article |
| format_ded117 |
Article, E-Article |
| format_degla1 |
E-Article |
| format_del152 |
Buch |
| format_del189 |
Article, E-Article |
| format_dezi4 |
Article |
| format_dezwi2 |
Article, E-Article |
| format_finc |
Article, E-Article |
| format_nrw |
Article, E-Article |
| _version_ |
1792346586169212928 |
| geogr_code |
not assigned |
| last_indexed |
2024-03-01T17:41:42.902Z |
| geogr_code_person |
not assigned |
| openURL |
url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=Topiramate+for+Weight+Reduction+in+Adolescents+With+Severe+Obesity&rft.date=2015-01-01&genre=article&issn=1938-2707&volume=54&issue=1&spage=19&epage=24&pages=19-24&jtitle=Clinical+Pediatrics&atitle=Topiramate+for+Weight+Reduction+in+Adolescents+With+Severe+Obesity&aulast=Kelly&aufirst=Aaron+S.&rft_id=info%3Adoi%2F10.1177%2F0009922814542481&rft.language%5B0%5D=eng |
| SOLR | |
| _version_ | 1792346586169212928 |
| author | Fox, Claudia K., Marlatt, Kara L., Rudser, Kyle D., Kelly, Aaron S. |
| author_facet | Fox, Claudia K., Marlatt, Kara L., Rudser, Kyle D., Kelly, Aaron S., Fox, Claudia K., Marlatt, Kara L., Rudser, Kyle D., Kelly, Aaron S. |
| author_sort | fox, claudia k. |
| container_issue | 1 |
| container_start_page | 19 |
| container_title | Clinical Pediatrics |
| container_volume | 54 |
| description | <jats:p> Background. Medications for use as an adjunct to lifestyle modification therapy (LSM) for severe adolescent obesity are limited. Topiramate results in weight reduction in adults with obesity, but has not been studied in adolescents. Objective. To examine the effect of topiramate plus LSM on body mass index (BMI) reduction in adolescents with severe obesity. Methods. Data for this retrospective chart review were collected from patients attending a pediatric weight management program who were treated with LSM plus topiramate for 3 months minimum. Mean BMI percent change from baseline was evaluated using t-tests. Results. Twenty-eight patients (mean age 15.2 ± 2.5 years, mean baseline BMI 46.2 ± 10.3 kg/m<jats:sup>2</jats:sup>) were identified for inclusion. The 6-month percent change in BMI was −4.9, 95% confidence interval (−7.1, −2.8), P < .001. Conclusions. Topiramate with concurrent LSM was associated with clinically meaningful BMI reduction in adolescents with severe obesity. Randomized controlled clinical trials examining efficacy and safety of topiramate for severe obesity in adolescents are needed. </jats:p> |
| doi_str_mv | 10.1177/0009922814542481 |
| facet_avail | Online |
| format | ElectronicArticle |
| format_de105 | Article, E-Article |
| format_de14 | Article, E-Article |
| format_de15 | Article, E-Article |
| format_de520 | Article, E-Article |
| format_de540 | Article, E-Article |
| format_dech1 | Article, E-Article |
| format_ded117 | Article, E-Article |
| format_degla1 | E-Article |
| format_del152 | Buch |
| format_del189 | Article, E-Article |
| format_dezi4 | Article |
| format_dezwi2 | Article, E-Article |
| format_finc | Article, E-Article |
| format_nrw | Article, E-Article |
| geogr_code | not assigned |
| geogr_code_person | not assigned |
| id | ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE3Ny8wMDA5OTIyODE0NTQyNDgx |
| imprint | SAGE Publications, 2015 |
| imprint_str_mv | SAGE Publications, 2015 |
| institution | DE-105, DE-14, DE-Ch1, DE-L229, DE-D275, DE-Bn3, DE-Brt1, DE-D161, DE-Gla1, DE-Zi4, DE-15, DE-Pl11, DE-Rs1 |
| issn | 0009-9228, 1938-2707 |
| issn_str_mv | 0009-9228, 1938-2707 |
| language | English |
| last_indexed | 2024-03-01T17:41:42.902Z |
| match_str | fox2015topiramateforweightreductioninadolescentswithsevereobesity |
| mega_collection | SAGE Publications (CrossRef) |
| physical | 19-24 |
| publishDate | 2015 |
| publishDateSort | 2015 |
| publisher | SAGE Publications |
| record_format | ai |
| recordtype | ai |
| series | Clinical Pediatrics |
| source_id | 49 |
| spelling | Fox, Claudia K. Marlatt, Kara L. Rudser, Kyle D. Kelly, Aaron S. 0009-9228 1938-2707 SAGE Publications Pediatrics, Perinatology and Child Health http://dx.doi.org/10.1177/0009922814542481 <jats:p> Background. Medications for use as an adjunct to lifestyle modification therapy (LSM) for severe adolescent obesity are limited. Topiramate results in weight reduction in adults with obesity, but has not been studied in adolescents. Objective. To examine the effect of topiramate plus LSM on body mass index (BMI) reduction in adolescents with severe obesity. Methods. Data for this retrospective chart review were collected from patients attending a pediatric weight management program who were treated with LSM plus topiramate for 3 months minimum. Mean BMI percent change from baseline was evaluated using t-tests. Results. Twenty-eight patients (mean age 15.2 ± 2.5 years, mean baseline BMI 46.2 ± 10.3 kg/m<jats:sup>2</jats:sup>) were identified for inclusion. The 6-month percent change in BMI was −4.9, 95% confidence interval (−7.1, −2.8), P < .001. Conclusions. Topiramate with concurrent LSM was associated with clinically meaningful BMI reduction in adolescents with severe obesity. Randomized controlled clinical trials examining efficacy and safety of topiramate for severe obesity in adolescents are needed. </jats:p> Topiramate for Weight Reduction in Adolescents With Severe Obesity Clinical Pediatrics |
| spellingShingle | Fox, Claudia K., Marlatt, Kara L., Rudser, Kyle D., Kelly, Aaron S., Clinical Pediatrics, Topiramate for Weight Reduction in Adolescents With Severe Obesity, Pediatrics, Perinatology and Child Health |
| title | Topiramate for Weight Reduction in Adolescents With Severe Obesity |
| title_full | Topiramate for Weight Reduction in Adolescents With Severe Obesity |
| title_fullStr | Topiramate for Weight Reduction in Adolescents With Severe Obesity |
| title_full_unstemmed | Topiramate for Weight Reduction in Adolescents With Severe Obesity |
| title_short | Topiramate for Weight Reduction in Adolescents With Severe Obesity |
| title_sort | topiramate for weight reduction in adolescents with severe obesity |
| title_unstemmed | Topiramate for Weight Reduction in Adolescents With Severe Obesity |
| topic | Pediatrics, Perinatology and Child Health |
| url | http://dx.doi.org/10.1177/0009922814542481 |